NEW YORK (GenomeWeb) – Biocept today priced its public offering of more than 4.9 million shares of common stock at $.68 per share.
Net proceeds from the offering, expected to close on or about Dec. 7, is anticipated to be $3 million, which will go toward working capital and other general corporate purposes, Biocept said. The firm noted that no warrants to purchase shares of its common stock will be issued to investors in connection with the offering.
Dawson James Securities and WestPark Capital were the offering's placement agents, with Dawson James acting as the lead placement agent. Biocept has agreed to issue the investment bank a warrant to purchase 246,296 shares of its common stock, with an exercise price equal to $.85 per share. The warrant can be exercised in six months.
In August, Biocept inked a deal to sell $2.2 million in stock and warrants to Hong Kong-based investment group Ally Bridge LB Healthcare Master Fund, and in March it reached agreements to sell $9.3 million in stock and warrants to institutional investors.
Biocept said last month that it ended its third quarter with $5.9 million in cash and cash equivalents.